NCT02381249

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: St. James's Hospital, Ireland · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

Improvements to treatment strategies for patients with cancers of the upper gastrointestinal tract have produced a large population of people who remain free from cancer recurrence in the long term following treatment. Surgery is the cornerstone of treatment for patients with these cancers, but while surgical removal of the tumour may offer the best chance of cure, these are major operations associated with specific long term complications. Weight loss and poor nutrition are common problems among patients who attain long-term cancer remission and cure after surgery. The mechanisms underlying these problems are not well understood and therefore treatment options are limited. Our research has demonstrated increased levels of chemical messengers (gut hormones) released from the gastrointestinal tract after meals in patients who have previously undergone this type of surgery. These chemical messengers play a role in controlling appetite and interest in food, and increased levels after surgery may reduce interest in eating. Understanding the role of gut hormones in the control of appetite may allow us to use certain medications to block gut hormones and hence increase appetite, allowing patients to eat more and regain weight, preventing nutritional problems after surgery. In this study, the investigators aim to determine whether exaggerated gut hormone secretion causes reduced appetite and interest in food after surgery. The information gained from this study may help us to develop treatments for patients with weight loss and nutritional problems after surgery.

Conditions

• Esophageal Neoplasms
• Stomach Neoplasms
• Weight Loss
• Malnutrition
• Pancreatic Neoplasms
• Duodenal Neoplasms

Interventions

Type	Name	Description
DRUG	Octreotide	Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
DRUG	Placebo	Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen

Timeline

• Start date: 2015-03-01
• Primary completion: 2018-03-01
• Completion: 2018-03-01
• First posted: 2015-03-06
• Last updated: 2023-11-27

Locations

2 sites across 2 countries: Ireland, Sweden